StockMarketWire.com - AstraZeneca said European health regulators issued a positive opinion to add a self-administration option for its asthma drug, inching the company closer to offering the treatment in a more convenient to many patients.

'The positive opinion for self-administration and the Fasenra pen is supported by the Phase III GREGALE and GRECO trials, and the Phase I AMES trial, respectively. The safety and tolerability of Fasenra in these trials were consistent with the known profile of the medicine,' the company said.

'We hope self-administration and the Fasenra pen will play important roles in helping physicians make treatment with biologic medicines accessible to more people with severe eosinophilic asthma,' it added.

AstraZeneca said anticipated a regulatory decision by the US Food and Drug Administration (FDA) on self-administration and the new pre-filled, single-use auto-injector device in the second half of 2019.


At 8:47am: [LON:AZN] AstraZeneca PLC share price was +21p at 6459p



Story provided by StockMarketWire.com